期刊
CURRENT MEDICINAL CHEMISTRY
卷 18, 期 19, 页码 2960-2968出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/092986711796150450
关键词
mTOR; mTORC1; mTORC2; AKT; ovarian cancer; rapamycin; rapalogs; everolimus; temsirolimus; ATP-competitive mTOR inhibitors
The mammalian target of rapamycin (mTOR) is frequently activated in epithelial ovarian cancer, and is regarded as an attractive therapeutic target for therapy. Preclinical investigations using rapamycin and its analogs have demonstrated significant growth-inhibitory effects on the growth of ovarian cancer both in the setting of monotherapy and in combination with cytotoxic agents. Based on promising preclinical data, mTOR inhibitors are currently being evaluated in several phase I/II trials in patients with ovarian cancer. In an effort to overcome resistance to rapamycin and its analogs, the novel ATP-competitive mTOR inhibitors have recently been developed. In this report, we review the scientific rationale and evidence for the potential clinical benefits provided by mTOR inhibitor therapy for patients with epithelial ovarian cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据